PVLA Pieris Corp: רווח נקי למניה ב-12 החודשים האחרונים

Pieris Pharmaceuticals (PVLA) relies on its proprietary Anticalin system, creating a protected patent perimeter for B2B collaboration. Historical YoY EPS growth over the last 12 months demonstrates profit dynamics, with the figure settling at 55.90. The company retains its team of top-tier biochemists through career advancement opportunities, while its environmental policy is limited to the safe disposal of laboratory waste.
PVLA (Pieris Pharmaceuticals Inc): פילוחים אנליטיים ודוחות לפי אינדיקטורים

This indicator measures the percentage change in net earnings per share over the last twelve months relative to the same period last year, reflecting the rate of shareholder value generation. For Pieris Pharmaceuticals (PVLA), an innovator in protein engineering with the Anticalin platform, the YoY TTM earnings per share trend serves as a marker for the commercialization efficiency of its cancer therapy developments.